Display options
Cite
Gómez-Sequeda N, Torres R, Ortiz C. Synthesis, characterization, and in vitro activity against . Nanotechnol Sci Appl. 2017;10:95-104doi: 10.2147/NSA.S96018.
Gómez-Sequeda, N., Torres, R., & Ortiz, C. (2017). Synthesis, characterization, and in vitro activity against . Nanotechnology, science and applications, 1095-104. https://doi.org/10.2147/NSA.S96018
Gómez-Sequeda, Nicolás, et al. "Synthesis, characterization, and in vitro activity against ." Nanotechnology, science and applications vol. 10 (2017): 95-104. doi: https://doi.org/10.2147/NSA.S96018
Gómez-Sequeda N, Torres R, Ortiz C. Synthesis, characterization, and in vitro activity against . Nanotechnol Sci Appl. 2017 May 16;10:95-104. doi: 10.2147/NSA.S96018. eCollection 2017. PMID: 28572725; PMCID: PMC5441665.
Copy Download .nbib Format: NLM
Share it on

Nanotechnol Sci Appl. 2017 May 16;10:95-104. doi: 10.2147/NSA.S96018. eCollection 2017.

Synthesis, characterization, and in vitro activity against .

Nanotechnology, science and applications

Nicolás Gómez-Sequeda, Rodrigo Torres, Claudia Ortiz

Affiliations

  1. School of Biology.
  2. School of Chemistry, Faculty of Sciences.
  3. School of Microbiology, Faculty of Health, Universidad Industrial de Santander, Bucaramanga, Santander, Colombia.

PMID: 28572725 PMCID: PMC5441665 DOI: 10.2147/NSA.S96018

Abstract

In this study, nanoparticles (NPs) of poly(lactic-co-glycolic acid) (PLGA) loaded with fluconazole (FLZ) and FLZ-NPs coated with the cationic polymer polyethylenimine (PEI) (FLZ-NP-PEI) were synthetized in order to improve antimycotic activity against four strains of

Keywords: double emulsion diffusion; drug delivery systems; minimal fungicide concentration; minimal inhibitory concentration; nanoparticles; polyethylenimine

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

References

  1. Int J Pharm. 2005 Jul 14;298(1):255-62 - PubMed
  2. Colloids Surf B Biointerfaces. 2016 Jun 1;142:400-7 - PubMed
  3. J Control Release. 2006 Jun 12;113(1):23-30 - PubMed
  4. J Phys Chem B. 2009 Aug 13;113(32):11179-85 - PubMed
  5. Biotechnol Appl Biochem. 2013 Jul-Aug;60(4):417-29 - PubMed
  6. J Nanobiotechnology. 2010 Sep 24;8:22 - PubMed
  7. J Microencapsul. 2004 Mar;21(2):203-11 - PubMed
  8. Pharm Res. 1999 Aug;16(8):1273-9 - PubMed
  9. Crit Care. 2009;13(4):R115 - PubMed
  10. Antimicrob Agents Chemother. 1998 Nov;42(11):3018-21 - PubMed
  11. J Antimicrob Chemother. 2013 May;68(5):1111-9 - PubMed
  12. Antimicrob Agents Chemother. 1995 Jan;39(1):1-8 - PubMed
  13. Nanomedicine. 2006 Mar;2(1):8-21 - PubMed
  14. J Control Release. 2001 Apr 2;71(2):203-11 - PubMed
  15. J Control Release. 2012 Aug 10;161(3):795-803 - PubMed
  16. J Pharm Sci. 1967 Oct;56(10):1238-42 - PubMed
  17. Eur J Pharm Biopharm. 2008 May;69(1):1-9 - PubMed
  18. N Engl J Med. 1991 Apr 11;324(15):1060-2 - PubMed
  19. Clin Infect Dis. 2003 Nov 1;37(9):1172-7 - PubMed
  20. Nat Methods. 2012 Jul;9(7):671-5 - PubMed
  21. Int J Antimicrob Agents. 2006 Jun;27 Suppl 1:7-11 - PubMed
  22. Biomaterials. 2011 Nov;32(32):8281-90 - PubMed
  23. Int J Antimicrob Agents. 2008 Nov;32 Suppl 2:S87-91 - PubMed
  24. J Control Release. 2009 Jan 19;133(2):90-5 - PubMed
  25. Int J Pharm. 2016 Aug 20;510(1):159-63 - PubMed
  26. J Nanobiotechnology. 2008 May 07;6:6 - PubMed
  27. Nanoscale Res Lett. 2011 Jul 12;6:447 - PubMed
  28. J Antimicrob Chemother. 2006 Oct;58(4):760-7 - PubMed
  29. Crit Rev Ther Drug Carrier Syst. 2004;21(5):387-422 - PubMed
  30. Clin Infect Dis. 2002 Oct 15;35(8):982-9 - PubMed
  31. J Immunol Methods. 1983 Dec 16;65(1-2):55-63 - PubMed
  32. Int J Nanomedicine. 2013;8:4521-31 - PubMed
  33. J Control Release. 2006 Aug 10;114(1):100-9 - PubMed
  34. Bioconjug Chem. 2008 Jan;19(1):145-52 - PubMed
  35. Crit Care Med. 2011 Apr;39(4):665-70 - PubMed
  36. Biol Pharm Bull. 2011;34(7):1129-33 - PubMed
  37. Int J Pharm. 2005 Sep 14;301(1-2):268-76 - PubMed
  38. Eur J Pharm Sci. 2012 Aug 15;46(5):522-9 - PubMed
  39. J Perinatol. 2005 Aug;25(8):531-6 - PubMed
  40. J Antimicrob Chemother. 2006 Mar;57(3):384-410 - PubMed
  41. Clin Microbiol Rev. 2007 Jan;20(1):133-63 - PubMed
  42. J Antimicrob Chemother. 2001 May;47(5):527-36 - PubMed
  43. J Nanosci Nanotechnol. 2006 Sep-Oct;6(9-10):3193-202 - PubMed
  44. Clin Infect Dis. 2004 Aug 1;39(3):309-17 - PubMed
  45. Curr Opin Microbiol. 2011 Aug;14(4):386-91 - PubMed
  46. Int J Pharm. 2008 Feb 12;349(1-2):152-60 - PubMed
  47. Saudi Pharm J. 2012 Apr;20(2):161-70 - PubMed
  48. Eur J Pharm Biopharm. 2004 Jul;58(1):1-6 - PubMed
  49. Acta Ophthalmol. 2010 Dec;88(8):901-4 - PubMed
  50. J Clin Microbiol. 2004 Oct;42(10):4419-31 - PubMed
  51. Drugs. 1995 Oct;50(4):658-90 - PubMed
  52. J Clin Microbiol. 1995 May;33(5):1104-7 - PubMed
  53. J Pharm Sci. 2000 May;89(5):614-26 - PubMed
  54. PLoS One. 2011;6(9):e24198 - PubMed
  55. Diagn Microbiol Infect Dis. 2003 Mar;45(3):203-6 - PubMed
  56. Drug Deliv Transl Res. 2014 Dec;4(5-6):400-8 - PubMed
  57. Clin Infect Dis. 2006 Jan 15;42(2):244-51 - PubMed
  58. Antimicrob Agents Chemother. 2004 Nov;48(11):4453-6 - PubMed
  59. Antimicrob Agents Chemother. 2001 Oct;45(10):2862-4 - PubMed
  60. J Pharm Sci. 2001 Jul;90(7):902-14 - PubMed
  61. Molecules. 2012 Apr 18;17(4):4612-24 - PubMed

Publication Types